Chemomab Therapeutics (CMMB) Tops Q3 EPS by 15c
Tweet
Share
E-mailGet Alerts CMMB Hot Sheet
Join SI Premium – FREE
Chemomab Therapeutics (NASDAQ: CMMB) reported Q3 EPS of ($0.04), $0.15 better than the analyst estimate of ($0.19).
For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Bit Digital (BTBT) Misses Q2 EPS by 27c
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
